Uniqure NV represents values of pioneering gene therapies and a commitment to transforming the lives of patients with severe genetic diseases. The company's corporate philosophy is centered around innovation, scientific excellence, and patient-centricity. Uniqure NV is dedicated to developing and delivering breakthrough treatments utilizing its proprietary gene therapy platform, focusing on addressing unmet medical needs. With a strong emphasis on collaboration and partnerships, Uniqure NV strives to advance the field of gene therapy, offering hope and improved quality of life to individuals affected by rare genetic disorders.

Uniqure NV is primarily present in various countries and regions across the globe. Some key locations where the company has a significant presence include the United States, Europe, and Canada. With its headquarters in the Netherlands, Uniqure NV has a strong foothold in Europe, particularly in countries like Germany, France, and the United Kingdom. Additionally, the company has expanded its reach to North America, with operations in the United States and Canada. Uniqure NV's global presence allows it to engage with a diverse range of markets and customers, facilitating its growth and impact in the field of genetic therapies.

Uniqure NV, a leading biopharmaceutical company, has achieved several significant milestones. It pioneered gene therapy and became the first company to gain approval for a gene therapy product in the European Union. Furthermore, Uniqure NV successfully launched Glybera, a groundbreaking treatment for patients with lipoprotein lipase deficiency. The company also forged strategic collaborations with top pharmaceutical companies to advance gene therapies for various diseases. Uniqure NV's dedication to innovation and its groundbreaking achievements have positioned the company as a pioneering force in the field of gene therapy, driving advancements in healthcare and offering hope for patients worldwide.

Uniqure NV is a pioneering gene therapy company that has made significant contributions in the field of genetic medicine. Founded in 1999, Uniqure NV has been dedicated to developing innovative treatments for rare genetic diseases and has successfully brought several therapies to market. With a focus on gene therapy platforms, the company has demonstrated its expertise in delivering long-lasting therapeutic effects. Uniqure NV has collaborated with leading research institutes and pharmaceutical companies to advance the field of gene therapy. Its commitment to improving patient outcomes through groundbreaking therapies has earned Uniqure NV a prominent position in the biotechnology industry.

The main competitors of Uniqure NV in the market are established companies such as Pfizer and Novartis. These pharmaceutical giants also specialize in gene therapy and have a significant presence in the biotechnology industry. Uniqure NV, a pioneering company in gene therapy, competes with these industry leaders in the development and commercialization of innovative treatments for genetic disorders. Their expertise and advancements in gene therapy contribute to the company's growth and sustenance in a fiercely competitive market.

Uniqure NV is primarily active in the biotechnology and pharmaceutical industries.

The business model of Uniqure NV focuses on developing and commercializing innovative gene therapies to treat severe genetic diseases. Uniqure NV utilizes its proprietary technology platform to create gene therapies that have the potential to provide long-lasting benefits. By using a targeted approach, Uniqure NV aims to address the underlying cause of genetic diseases, offering potential cures rather than simply managing symptoms. The company collaborates with academic institutions, pharmaceutical companies, and healthcare organizations to advance its research and development efforts. Uniqure NV's business model revolves around the development, manufacturing, and commercialization of gene therapies to improve the lives of patients affected by genetic disorders.

P/E santykio šiuo metu Uniqure apskaičiuoti negalima.

KUV šiuo metu negali būti apskaičiuotas Uniqure.

AlleAktien kokybės įvertis Uniqure yra 5/10.

Pajamos šiuo metu negali būti apskaičiuotos Uniqure.

Pelnas šiuo metu negali būti apskaičiuotas Uniqure.

Uniqure NV is a leading biotechnology company specializing in the development of innovative gene therapies for genetic diseases. The company utilizes its proprietary gene therapy platform to develop life-changing therapies for patients in various therapeutic areas. The business model of Uniqure is based on collaboration with leading academics and companies in the biotech industry, as well as its own research and development strategy. The company has a variety of partnerships with pharmaceutical and biotech companies to expand its portfolio of gene therapy products and bring them to market. Uniqure is one of the few companies using gene editing technology to treat genetic diseases. This technology allows for the correction or replacement of specific genes in human cells. This is a breakthrough in gene therapy, as previous approaches often only provided symptomatic treatment. Uniqure's product portfolio currently includes a wide range of gene therapy products in various stages of clinical development and therapeutic areas. Some of these therapies are already in phase III clinical trials, focusing on diseases such as hemophilia, Huntington's disease, and spinal muscular atrophy. Uniqure also focuses on developing gene therapies for rare diseases that have been previously unmet medical needs. These niche markets offer enormous opportunities for the company, as they are often overlooked by other companies due to their low potential. The business model of Uniqure also includes a strong patent and technology protection strategy to ensure long-term competitiveness. The company places a strong emphasis on regulatory compliance and collaboration with regulatory authorities to facilitate the approval of its treatment products. The company has a variety of financing options, including venture capital and public financing. Uniqure also has a strong partnership with multinational pharmaceutical companies such as Bristol-Myers Squibb, who support the company in bringing its gene therapy products to the global market. Overall, the business model of Uniqure NV offers a wide range of innovative gene therapies for the treatment of genetic diseases, as well as a strong protection strategy for its technologies and patents. With strong partnerships and a broad research and development strategy, the company offers enormous opportunities for growth in the coming years.

Uniqure moka dividendą 0 USD, kuris yra paskirstytas per išmokas per metus.

Dividenda šiuo metu negali būti apskaičiuota Uniqure arba įmonė dividendų nemoka.

Uniqure ISIN yra NL0010696654.

Uniqure WKN yra A1XDTV.

Uniqure akcijų simbolis yra QURE.

Per paskutinius 12 mėnesių Uniqure išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams Uniqure tikėtina išmokės dividendus, kurie sudarys 0 USD.

Uniqure šiuo metu yra dydžio dividendų grąža.

Uniqure moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Uniqure per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 USD. Tai atitinka 0 % dividendų grąžos procentą.

Uniqure priskiriamas sektoriui "Sveikata".

Norėdamas gauti paskutinį Uniqure dividendą nuo 2024-12-17, kurio dydis yra 0 USD, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-12-17.

Paskutinės dividendų išmokėjimas įvyko 2024-12-17.

2023 metais Uniqure išmokėjo 0 USD dividendų.

Uniqure dividendai yra mokami USD.